Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets... Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers. Show more
Expect ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, to complete enrollment in the first half of 2025Expect to announce topline...
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble...
NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel...
Late-breaking presentation highlights the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary amyloid PET scans and lumbar puncture...
- Presentation to focus on use of validated pTau217 assay in participant screening process for Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer’s disease - Late-breaking presentation...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.16 | -6.32411067194 | 2.53 | 2.66 | 2.23 | 203584 | 2.39863867 | CS |
| 4 | -0.37 | -13.503649635 | 2.74 | 3.31 | 2.23 | 207206 | 2.81548803 | CS |
| 12 | -0.43 | -15.3571428571 | 2.8 | 3.31 | 2.1511 | 192708 | 2.6178035 | CS |
| 26 | -1.46 | -38.1201044386 | 3.83 | 3.9 | 2.08 | 309828 | 2.67989653 | CS |
| 52 | 0.01 | 0.423728813559 | 2.36 | 5.09 | 2.08 | 337134 | 3.13284968 | CS |
| 156 | -7.57 | -76.1569416499 | 9.94 | 11.3099 | 1.8101 | 429810 | 6.25358517 | CS |
| 260 | -22.7 | -90.5464698843 | 25.07 | 26.98 | 1.8101 | 399062 | 6.75469201 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
